Bioavailability of clindamycin during peritoneal dialysis

Area of Science:

• Pharmacology
• Nephrology
• Infectious Diseases

Background:

• Clindamycin phosphate requires phosphate ester bond cleavage for biological activity.
• Peritoneal dialysis (PD) is a renal replacement therapy.
• Effective antibiotic delivery during PD is crucial for preventing and treating infections.

Purpose of the Study:

• To evaluate the bioavailability of active clindamycin during peritoneal dialysis in a rat model.
• To determine the conversion rate of clindamycin phosphate to active clindamycin in the presence of PD.
• To assess the efficacy of clindamycin phosphate in treating peritonitis during PD.

Main Methods:

• A rat model was utilized to study clindamycin phosphate pharmacokinetics during peritoneal dialysis.
• Intravenous administration of clindamycin phosphate was compared to its administration via dialysis fluid.
• Blood and dialysate levels of active clindamycin were measured with and without induced peritonitis.

Main Results:

• Intravenous clindamycin phosphate achieved peak blood levels of 15-20 µg/ml without PD.
• With PD, blood levels of active clindamycin were consistently below 5 µg/ml.
• Adding clindamycin phosphate to dialysis fluid resulted in <5 µg/ml in return fluid, and <15 µg/ml even with peritonitis.
• Peritoneal administration yielded <5 µg/ml active clindamycin in blood.

Conclusions:

• The conversion of clindamycin phosphate to its active form is significantly impaired during peritoneal dialysis.
• Low systemic and local concentrations of active clindamycin suggest it is not suitable for use during PD.
• Alternative antimicrobial agents are recommended for patients undergoing peritoneal dialysis to prevent serious infections.